An Open-Label Study Of Ruxolitinib Given With Chemotherapy In Patients With Advanced Solid Tumors

Study Overview

An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors

This is a study of ruxolitinib in combination with gemcitabine with or without nab-paclitaxel administered to patients with advanced or metastatic pancreatic cancer. The study will be conducted in two parts. Part 1 of the study will evaluate the safety, tolerability and pharmacokinetics (PK) of ruxolitinib when given as described to patients with advanced or metastatic pancreatic cancer. A goal of Part 1 will be to identify the maximally tolerated dose (MTD) of ruxolitinib when given with gemcitabine with or without nab-paclitaxel. This dose will be selected for use in Part 2 of the study. Part 2 of the study will further evaluate the safety, tolerability, PK and preliminary clinical activity of ruxolitinib at the dose defined in Part 1 used in combination with gemcitabine with or without nab-paclitaxel in subjects with advanced or metastatic pancreatic cancer. After multiple challenges of trial conduct, by mutual agreement between investigators and sponsor, dose escalation ended after Cohort B1, RUX 10 mg twice daily (BID) - GCSF in October 2014. Therefore, the MTD was not reached. No safety issues led to the decision to stop further enrollment. Because of the early study termination, samples for pharmacokinetics and pharmacodynamics, and computed tomography for tumor burden were collected, but not analyzed; analysis data are not available. The data cutoff for this posting is 22 SEP 2015. As of the data cutoff, 1 subject was receiving treatment in the study and had been enrolled for 47 weeks. This subject had their end of treatment visit in AUG 2016. A comparison of this subjects' safety data after the cutoff date showed no clinically meaningful differences (eg, adverse events) compared with safety results that are summarized here.

N/A

Solid Tumors
Pancreatic Cancer

DRUG: ruxolitinib
DRUG: gemcitabine
DRUG: nab-paclitaxel
DRUG: filgrastim

INCB 18424-144

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates	Results Reporting Dates	Study Record Updates
First Submitted 2013-03-28	Results First Submitted 2016-09-20	Last Update Submitted that met QC Criteria 2018-01-15
First Submitted that Met QC Criteria 2013-04-01	Results First Submitted that Met QC Criteria 2017-03-02	Last Update Posted (ACTUAL) 2018-02-12
First Posted (ACTUAL) 2013-04-02	Results First Posted 2017-04-13	Last Verified 2018-01

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment

Allocation:
Non Randomized

Interventional Model:
Single Group

Masking:
None

Arms and Interventions

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: Regimen A -ruxolitinib, gemcitabine Ruxolitinib (RUX) was self-administered by the subject orally in the morning and evening, approximately 12 hours apart, without regard to food. The morning dose of RUX was to be taken before the chemotherapy infusion, Gemcitabine IV, on days when they wer	DRUG: ruxolitinib DRUG: gemcitabine Other names: Gemzar®
EXPERIMENTAL: Regimen B-ruxolitinib, gemcitabine, nab-paclitaxel, filgrastim Ruxolitinib (RUX) was self-administered by the subject orally in the morning and evening, approximately 12 hours apart, without regard to food. Gemcitabine was provided as open-label, commercial product and was administered intravenously (IV) over 30 min	DRUG: ruxolitinib DRUG: gemcitabine Other names: Gemzar® DRUG: nab-paclitaxel Other names: Abraxane® DRUG: filgrastim Prophylactic GCSF support was filgrastim and was given in Cycle 1 on Days 2 to 5, 9 to 12, and 16 to 19, unless chemotherapy was held for toxicity, then prophylactic GCSF support was also held.

Participant Group/Arm

Intervention/Treatment

EXPERIMENTAL: Regimen A -ruxolitinib, gemcitabine

Ruxolitinib (RUX) was self-administered by the subject orally in the morning and evening, approximately 12 hours apart, without regard to food. The morning dose of RUX was to be taken before the chemotherapy infusion, Gemcitabine IV, on days when they wer

DRUG: ruxolitinib

DRUG: gemcitabine

Other names: Gemzar®

EXPERIMENTAL: Regimen B-ruxolitinib, gemcitabine, nab-paclitaxel, filgrastim

Ruxolitinib (RUX) was self-administered by the subject orally in the morning and evening, approximately 12 hours apart, without regard to food. Gemcitabine was provided as open-label, commercial product and was administered intravenously (IV) over 30 min

DRUG: ruxolitinib

DRUG: gemcitabine

Other names: Gemzar®

DRUG: nab-paclitaxel

Other names: Abraxane®

DRUG: filgrastim

Prophylactic GCSF support was filgrastim and was given in Cycle 1 on Days 2 to 5, 9 to 12, and 16 to 19, unless chemotherapy was held for toxicity, then prophylactic GCSF support was also held.

Primary Outcome Measures	Measure Description	Time Frame
Percentage of Participants With Adverse Events That Are Defined as Dose Limiting Toxicities (DLTs)	Toxicities occurring during the first treatment cycle (Cycle 1) defined tolerability. Within each cohort, subjects were considered evaluable if they had received at least 40 of 56 planned doses of RUX during the 28-day surveillance period and received 2 of the 3 planned doses of chemotherapy (gemcitabine and/or gemcitabine and nab-paclitaxel) at the assigned dose level, or they had experienced a DLT.	Approximately 28 days

Secondary Outcome Measures	Measure Description	Time Frame
Plasma Concentrations Will be Used to Estimate Peak Plasma Concentration (Cmax) and Area Under the Plasma Concentration Curve (AUC).		Day 1 and Day 8
Plasma Concentration of Tumor Specific Biomarkers and Cytokines Before and During Treatment.		Up to 6 months
Clinical Activity as Measured by the Greatest Decrease in Tumor Burden Compared to Baseline.		Approximately 6 months
Percentage of Participants With a Best Response by RECIST Criteria	Best response was determined on the subject level using the highest overall response achieved post-baseline. In the case of stable disease (SD), measurements had to meet the SD criterion at least once after study entry at a minimum interval of 49 days. Subjects who failed to meet this criterion had best response of progressive disease (PD) if the next available RECIST evaluation after the initial scan indicated PD or not evaluable (NE) if no additional RECIST evaluations were available. Complete Response (CR) and Partial Response (PR) defined by the Response Evaluation Criteria in Solid Tumor (RECIST) criteria. CR: Disappearance of all target and nontarget lesions. PR: At least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter, or persistence of 1 or more nontarget lesion(s) or/and maintenance of tumor marker level above the normal limits.	every 2 cycles starting at Cycle 3 Day 1 up to approximately 4 to 6 months
Percentage of Responders	Duration of response was measured as the time from the first overall response contributing to an objective response to the first overall response of progressive disease (PD) occurring after the first overall response contributing to the objective response.	Randomization to clinical cutoff 22Sept2015 (approx 244 days)
Duration of Response	Duration of response was the time from the first overall response contributing to an objective response to the first overall response of progressive disease (PD) occurring after the first overall response contributing to the objective response. Confidence intervals for median duration of response were calculated using the method of Brookmeyer and Crowley (1982).	Randomization to clinical cutoff 22Sept2015 (approx 244 days)

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

Male or female, 18 years or older
Histologically or cytologically confirmed adenocarcinoma of the pancreas
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
Requirements for prior therapy as outlined below:

Enrollment into Regimen A: received no more than 1 prior chemotherapy regimen for advanced or metastatic disease (not including neoadjuvant and/or adjuvant therapy)
Enrollment into Regimen B: received no prior chemotherapy for advanced or metastatic disease (not including neoadjuvant and/or adjuvant therapy)
Adequate renal, hepatic, and bone marrow function without blood product or hematopoietic growth factor support:
Able to swallow and retain oral medication

Any known contraindications to the use of gemcitabine (for enrollment in Regimen A or B) or nab-paclitaxel (for enrollment into Regimen B).
Evidence of uncontrolled brain metastases or history of uncontrolled seizures.
Ongoing radiation therapy and/or radiation therapy administered within 28 days of enrollment. Subjects who have received radiation to the spine, pelvis, ribs, or femur should be discussed with the sponsor, as extensive radiation to marrow forming region may compromise a subject's ability to tolerate myelosuppressive chemotherapy. Subjects who have ongoing radiotherapy-related toxicities are not eligible.
Subjects who participated in any other study in which receipt of an investigational study drug occurred within 28 days or 5 half-lives (whichever is longer) prior to first dose.
Current or previous other malignancy within 2 years of study entry, except cured basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix, or other noninvasive malignancy without sponsor approval.
Inability to swallow food or any condition of the upper GI tract that precludes administration of oral medications.
Recent (≤ 3 months) history of partial or complete bowel obstruction.
Unwilling to be transfused with blood components.
Known history of Hepatitis B or C infection or HIV infection.
Presence of ≥ Grade 2 neuropathy

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

STUDY_DIRECTOR: Fitzroy Dawkins, M.D., Incyte Corporation

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

Learn

Resources

PatientS

Caregivers

Clinical Trial Record